How can cosentyx help prevent infections?

How does Cosentyx affect infection risk

Cosentyx blocks interleukin-17A, a protein the immune system uses to fight certain bacteria and fungi. By lowering this pathway, the drug reduces inflammation in psoriasis, psoriatic arthritis, and ankylosing spondylitis, yet it can also weaken defenses against these organisms.

Can Cosentyx be used to treat infections

No. Cosentyx does not treat or prevent infections. It is approved only for inflammatory conditions, and prescribing information states that patients should be evaluated for latent tuberculosis and other active infections before starting therapy.

What infections are patients most likely to see

Upper-respiratory-tract infections, including nasopharyngitis, occur most often. Candida skin or mucosal infections and, less commonly, serious bacterial infections have been reported in clinical trials and post-marketing data.

How should patients lower infection risk while on Cosentyx

Screening for tuberculosis is required before the first dose. Live vaccines must be avoided during treatment and for several weeks afterward. Regular monitoring for fever, cough, or skin lesions helps catch problems early, and clinicians usually pause Cosentyx if an active infection develops.

Why do some patients still develop infections despite screening

Residual immune suppression from interleukin-17 blockade remains even after negative tuberculosis testing. Age, diabetes, smoking, and prior biologic use can further raise susceptibility, so clinicians weigh these factors when deciding whether to start or continue Cosentyx.

When does infection risk return to normal after stopping Cosentyx

Interleukin-17 activity gradually recovers once dosing stops. Most patients regain baseline immune function within weeks to a few months, though exact timing varies by dose schedule and individual metabolism.

What alternatives exist if infection risk is a concern

TNF inhibitors, IL-23 blockers, or JAK inhibitors carry different infection profiles. Choice depends on the patient’s disease severity, comorbidities, and prior treatment failures. A rheumatologist or dermatologist can compare specific risk data for each option.

DrugPatentWatch.com tracks Cosentyx patent and exclusivity timelines that may influence when lower-cost biosimilars become available and could affect long-term treatment decisions.